Advisor Group Holdings, Inc. Verastem, Inc. Transaction History

Advisor Group Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.39 - $0.71 $35 - $63	-90 Reduced 0.47%	19,175 $8,000
Q4 2022 Feb 10, 2023	SELL	$0.33 - $10.44 $355 - $11,254	-1,078 Reduced 5.3%	19,265 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $13,641 - $165,480	-14,828 Reduced 42.16%	20,343 $17,000
Q1 2022 May 04, 2022	BUY	$1.06 - $2.1 $3,801 - $7,530	3,586 Added 11.35%	35,171 $50,000
Q3 2021 Nov 05, 2021	BUY	$2.54 - $4.07 $7,985 - $12,796	3,144 Added 11.05%	31,585 $97,000
Q2 2021 Aug 02, 2021	BUY	$2.57 - $4.85 $7,846 - $14,807	3,053 Added 12.03%	28,441 $115,000
Q1 2021 May 13, 2021	BUY	$1.9 - $2.82 $1,326 - $1,968	698 Added 2.83%	25,388 $63,000
Q4 2020 Feb 10, 2021	BUY	$1.15 - $2.4 $20,700 - $43,200	18,000 Added 269.06%	24,690 $52,000
Q3 2020 Nov 12, 2020	SELL	$1.11 - $1.68 $13,320 - $20,160	-12,000 Reduced 64.21%	6,690 $8,000
Q2 2020 Aug 14, 2020	SELL	$1.69 - $4.2 $24,045 - $59,757	-14,228 Reduced 43.22%	18,690 $32,000
Q1 2020 May 18, 2020	BUY	$1.26 - $3.38 $41,476 - $111,262	32,918 New	32,918 $86,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.